Evaluation of AZD5335 Monotherapy and Combination Therapy in Patients with Platinum-Resistant Recurrent Ovarian Cancer and Lung Adenocarcinoma

The primary objective of this clinical trial is to evaluate the **safety** and **efficacy** of AZD5335, both as a monotherapy and in combination with other treatments, in individuals diagnosed with **platinum-resistant recurrent (PRR) ovarian cancer** and **lung adenocarcinoma**. This study aims to determine the therapeutic potential of AZD5335 in these specific solid tumors, which are known for their challenging treatment landscape and limited response to conventional therapies. Understanding the safety profile and therapeutic efficacy of AZD5335 is clinically relevant as it may offer new treatment avenues for patients with these resistant cancer types.

The clinical trial involves a total of **336 participants** diagnosed with **platinum-resistant recurrent ovarian cancer** and **lung adenocarcinoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process for the trial population is not explicitly described, and the sponsor has not provided detailed inclusion or exclusion criteria. The study aims to gather data from a diverse group of individuals affected by these specific medical conditions.

The clinical trial is designed to evaluate the safety and efficacy of **AZD5335** alone and in combination with other treatments in individuals diagnosed with **platinum-resistant recurrent (PRR) ovarian cancer** and **lung adenocarcinoma**. This is a Phase 1 trial, which will be conducted as a randomized, double-blind, controlled study. The estimated recruitment start date is December 31, 2023, with an anticipated completion date of October 1, 2028, indicating a total trial duration of approximately five years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. The trial will include multiple follow-up visits to monitor the safety, tolerability, and pharmacokinetics of the investigational product. These visits will be scheduled at regular intervals throughout the study period. The end-of-study visit will occur after the final treatment cycle, where comprehensive assessments will be conducted to evaluate the overall outcomes of the trial.

The expected length of participant involvement will vary depending on individual response to treatment and the specific protocol requirements. Participants may be subject to early termination from the study if they experience significant adverse events, demonstrate disease progression, or fail to comply with study procedures. The trial aims to gather critical data to inform future research and potential therapeutic applications for the targeted conditions.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. The absence of these details suggests that the focus is primarily on the experimental medication, although further clarification would be necessary to confirm this aspect of the trial design.

Due to the lack of specific information, it is not possible to provide additional relevant details about drug administration, dosing schedules, or participant compliance monitoring. The trial documentation does not include any data on the product's authorization status, pharmaceutical form, or the origin of the active substances involved in the study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on December 31, 2023, with an estimated completion date of October 1, 2028. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a range of parameters such as **biomarker** levels or symptom improvement scores to gather initial efficacy data. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial's design and execution will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy data collected.